Karyopharm Therapeutics
KPTI
73 hedge funds and large institutions have $251M invested in Karyopharm Therapeutics in 2017 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 36 increasing their positions, 20 reducing their positions, and 12 closing their positions.
80% more repeat investments, than reductions
Existing positions increased: 36 | Existing positions reduced: 20
52% more call options, than puts
Call options by funds: $1.24M | Put options by funds: $816K
0.34% less ownership
Funds ownership: 4.27% → 3.93% (-0.34%)
9% less funds holding
Funds holding: 80 → 73 (-7)
27% less capital invested
Capital invested by funds: $345M → $251M (-$93.3M)
50% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 12
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$4.47M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$3.8M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
+$2.79M |
| 4 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
+$2.62M |
| 5 |
TCM
Tekla Capital Management
Boston,
Massachusetts
|
+$1.49M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
-$4.76M |
| 2 |
EI
EAM Investors
Solana Beach,
California
|
-$3.46M |
| 3 |
Ameriprise
Minneapolis,
Minnesota
|
-$1.13M |
| 4 |
Russell Investments Group
London,
United Kingdom
|
-$962K |
| 5 |
SCA
Secor Capital Advisors
New York
|
-$781K |
KPTI Hedge Fund Activity: Q2 2017 in Review
73 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in Karyopharm Therapeutics (KPTI) for Q2 2017, worth a combined $251M — down 27% from $345M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of KPTI and 6 opened new positions — a net loss of 6 holders — while 20 trimmed existing stakes and 36 added.
The largest buyer was BlackRock, adding an estimated $4.47M. The largest seller was JP Morgan Chase, cutting an estimated $4.76M.
- 73 institutional investors held Karyopharm Therapeutics (KPTI) as of Q2 2017, down from 80 in Q1 2017.
- Funds reported $251M of Karyopharm Therapeutics stock for Q2 2017, down 27% quarter-over-quarter.
- 6 funds opened new Karyopharm Therapeutics positions in Q2 2017 and 12 closed out, a net change of -6 holders.
- The largest Karyopharm Therapeutics buyer in Q2 2017 was BlackRock, an estimated $4.47M added.
- The largest Karyopharm Therapeutics seller in Q2 2017 was JP Morgan Chase, an estimated $4.76M sold.
Based on aggregated 13F filings for Q2 2017.